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DNAtopoisomerase II (topo II) regulates the topological state
ofDNAand is necessary forDNA replication, transcription, and
chromosome segregation. Topo II has essential functions in cell
proliferation and therefore is a critical target of anticancer
drugs. In this study, using Phos-tag SDS-PAGE analysis in fis-
sion yeast (Schizosaccharomyces pombe), we identified casein
kinase II (Cka1/CKII)–dependent phosphorylation at theC-ter-
minal residues Ser1363 and Ser1364 in topo II.We found that this
phosphorylation decreases the inhibitory effect of an anticancer
catalytic inhibitor of topo II, ICRF-193, on mitosis. Consistent
with the constitutive activity of Cka1/CKII, Ser1363 and Ser1364
phosphorylation of topo II was stably maintained throughout
the cell cycle. We demonstrate that ICRF-193–induced chro-
mosomalmis-segregation is further exacerbated in two temper-
ature-sensitive mutants, cka1–372 and cka1/orb5-19, of the
catalytic subunit of CKII or in the topo II nonphosphorylatable
alanine double mutant top2-S1363A,S1364A but not in cells
of the phosphomimetic glutamate double mutant top2-
S1363E,S1364E. Our results suggest that Ser1363 and Ser1364 in
topo II are targeted by Cka1/CKII kinase and that their phos-
phorylation facilitates topo II ATPase activity in the N-terminal
region, which regulates protein turnover on chromosomeDNA.
BecauseCKII-mediated phosphorylation of the topo II C-termi-
nal domain appears to be evolutionarily conserved, including in
humans, we propose that attenuation of CKII-controlled topo II
phosphorylation alongwith catalytic topo II inhibitionmay pro-
mote anticancer effects.
DNA topoisomerase II (topo II)3 passes dsDNA through the
other dsDNA by transiently breaking and rejoining the strand
(1–3). In eukaryotic cells, topo II relaxes supercoiled DNA
and catalyzes catenation–decatenation, as well as knotting–
unknotting of circular DNA. The supercoil relaxation activity
of topo II is crucial for resolving negatively supercoiled DNA,
which forms behind replication or transcription machinery,
and also positively supercoiled DNA, which forms in front of it.
In mitosis, proper separation of replicated sister chromatids
requires topo II decatenation activity (4–6). Using Schizosac-
charomyces pombe top2 temperature-sensitive (ts) and cold-
sensitive (cs) mutants, it has been proposed that topo II con-
tinuously acts on chromosomes to disentangle topologically
intertwined sister chromatids throughout mitosis (7–10).
Topo II is a critical target for anticancer chemotherapy
because of its essential role in cell proliferation. Two types of
topo II inhibitor are widely known as anticancer drugs (11–13).
The best known topo II–targeting drugs are etoposide and
doxorubicin, which inhibit the rejoining step after cleaving one
of the dsDNA strands (14). These drugs induce DNA double-
stranded breakage and are thus termed “topo II poisons.” In
contrast, “catalytic inhibitors” block ATPase activity prerequi-
site for dsDNA release from the DNA–topo II covalent com-
plex after DNA rejoining (11). ICRF-193, a bisdioxopiperazine
derivative (meso-4,4-(2,3-butanediyl)-bis (2,6-piperazinedi-
one)), is a catalytic topo II inhibitor (15, 16). This drug causes
mitotic chromosomal mis-segregation but does not interfere
withDNA replication, resulting in a ploidy increase inmamma-
lian cells (17–19). In fission yeast, ICRF-193 inhibits mitotic
chromosomal segregation accompanied by unique spindle
dynamics, leading to a ploidy increase (20). Thus, the effect of
anticancer catalytic topo II inhibitors onmitotic chromosomes
and spindle dynamics is validated and conserved from yeast to
human cells.
Topo II is a phosphoprotein, and its evolutionarily divergent
C-terminal domain (CTD) is preferentially phosphorylated in
budding yeast, fission yeast, Drosophila, and human cells (21–
28). In budding yeast and human cultured cells, casein kinase II
(CKII) phosphorylates the topo II CTD (26, 29). The topo II
CTD has been thought to be dispensable for enzymatic activity
itself, acting as a regulator of topo II through nuclear localiza-
tion or chromosomal targeting of topo II proteins (30–32). In
S. pombe, papain digestion of topo II protein produces an30-
kDa C-terminal hydrophilic domain in which multiple phos-
phorylation sites have been predicted (Fig. 1A) (33). The phys-
iological significance of topo II CTD phosphorylation in this
organism has been unclear because topo II dephosphorylated
by phosphatase treatment is still enzymatically active (25).
In this study, we identified CKII-dependent phosphorylation
sites in the CTD of S. pombe topo II protein using Phos-tag
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Figure 1. Phos-tag analyses reveal that DNATop2 Ser1363 and Ser1364 in the C-terminal charged region are phosphorylated. A, schematic of the fission
yeast Top2 polypeptide. Top2 consists of a catalytic core and acidic/basic clusters at both ends of the protein. The catalytic core contains two evolutionarily
conserved domains, an ATP-binding hydrolytic domain (green), and a DNA-binding cleavage domain (red). B, Phos-tag analysis of FLAG-tagged Top2 protein.
Extracts of a cs nda3-KM311 -tubulin mutant strain expressing Top2–3FLAG were prepared from asynchronously cultured (AS) and mitotically arrested cells
(M) and run on SDS-PAGE gels in the presence or absence of 25 M Phos-tag. The untagged strain was used as a negative control. Each sample was preincu-
bated with phage  PPase () or buffer (). Ponceau staining served as a loading control. Anti-FLAG antibodies detected phosphorylated Top2 proteins
(Top2-P) in asynchronous andmitotically arrested cells. The position of themarker band is not indicated in the phos-tag blot because themarker proteinswere
also highly phosphorylated, and precise positions were unclear. C, Phos-tag analysis of truncated Top2 proteins. Top panel, N- or C-terminally truncated
Top2-FLAG proteins were mildly overproduced under the inducible nmt promoter (plasmid Rep81) in the absence of thiamine in WT S. pombe cells. A strain
containingonly thevectorwasusedas a control. Positionsof unphosphorylatedbandsare indicatedby redarrowheads.Bottompanel, truncated fragments and
their phosphorylation (Phospho) status are indicated (, phosphorylated;, unphosphorylated). A red dashed box shows the predicted region of phosphor-
ylation. aa, amino acids.D, C-terminally truncated Top2 proteinswere expressed under the native promoter with the chromosomally integrated FLAG-tagged
gene. Top2 C terminus phosphorylation is predicted between residues 1352 and 1391 (double-headed arrow in the bottom panel). E, the amino acid sequence
around Ser1363 and Ser1364 of S. pombe Top2, with seven-amino-acid sequences. The consensus target sequence for CKII is shown. Xl, Xenopus laevis;Hs,Homo
sapiens;Dm,Drosophilamelanogaster; Ce, Caenorhabditis elegans; At, Arabidopsis thaliana; Sp, Schizosaccharomyces pombe; Sc, Saccharomyces cerevisiae. F, the
Phos-tag–mediated mobility shift of the Top2 protein disappeared as a result of alanine substitutions for Ser1363 and Ser1364. The intensity of the smeary
phosphorylated Top2 bands was quantified and is indicated relative to the background.
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SDS-PAGE analysis and specific anti-phospho antibodies. We
present evidence that phosphorylation at these sites diminishes
the effect of an anticancer catalytic topo II inhibitor, ICRF-193,
on mitotic chromosome segregation.
Results
Phos-tag analysis of S. pombe DNA Topoisomerase II (Top2)
identified residues Ser1363 and Ser1364 as phosphorylation
sites in the Top2 C-terminal region
To detect phosphorylation of S. pombe Top2, we first per-
formed Phos-tag analysis to identify phosphorylated protein
bands in SDS-PAGEby decreasing themobility of phosphopro-
teins (34). We used the Top2–3FLAG strain, which contains a
chromosomally integrated 3FLAG-tagged top2 gene under
the native promoter (35). Cell extracts were prepared from
asynchronously cultured (33 °C, 70–80% of cells are in inter-
phase) or mitotically arrested (20 °C) -tubulin cs mutant
nda3-KM311 cells. As shown in immunoblot patterns using
anti-FLAG antibodies (Fig. 1B), lower-mobility bands of Top2–
3FLAGwere produced in the presence of Phos-tag (Fig. 1B, top
panel) in both asynchronously cultured and mitotic cells,
whose mobility increases after treatment with  protein phos-
phatase (PPase). Mitotic phosphorylation of Top2–3FLAGwas
slightly increased compared with that in asynchronous cells.
These results confirmed that S. pombe Top2 is a phosphopro-
tein (25).
Todeterminewhich subdomainofTop2protein isphosphor-
ylated, the degree of phosphorylation in N-terminally or C-ter-
minally truncated mutant proteins was investigated. Cell
extracts were prepared from WT cells transformed with plas-
mids carrying the truncated FLAG-tagged top2 genes. Mildly
overproduced N-truncated Top2 mutant proteins (N75 or
N231) produced smeary low-mobility bands that disappeared
after PPase treatment as well as full-length Top2 proteins (Fig.
1C, 6% gel). However, C-truncated mutant proteins (C1311
or C1197) abolished the phosphorylation shift of the pro-
tein bands. In addition, the short fragments N1198 and
N1312, which correspond to the C-terminal 175 or 289
residues, produced multiple low-mobility bands (Fig. 1C,
12% gel), suggesting that the Top2 C terminus 289 residues
are highly phosphorylated.
We further performed Phos-tag analysis of C-terminally
truncated Top2 proteins under the native promoter using
a stepwise truncation series. Cells expressing C1448 and
C1392 Top2 protein produced phosphorylation bands in the
absence of PPase treatment (Fig. 1D). In contrast, C1352 and
C1311 proteins showed no detectable phosphorylation. Thus,
phosphorylation sites of Top2were predicted between residues
1353 and 1392 in the C-terminal region.
Between residues 1353 and 1392, two putative CKII target
residues, Ser1363 and Ser1364, have been predicted (25). These
residues fit the consensus target sequence for CKII phosphor-
ylation (S/T-X-X-D/E, where X indicates any amino acid) (36–
38) (Fig. S1). Although these serine residues are not conserved
among seven organisms, acidic residues are enriched around
them (Fig. 1E). To test whether Ser1363 and Ser1364 were phos-
phorylated, we constructed S. pombe strains in which Ser1363
and/or Ser1364 were chromosomally replaced with alanine,
which is unphosphorylatable. As a result of Phos-tag analysis
(Fig. 1F), single S1363A or S1364A mutant proteins signifi-
cantly reduced the smeary phosphorylated bands in the absence
of PPase. In double S1363A S1364Amutant cells, the mobil-
ity shift of the Top2 bands was hardly seen. These results indi-
cate that both Ser1363 and Ser1364 in the S. pombeTop2CTDare
phosphorylated.
Detection of Top2 phosphorylation sites byMS
To verify the Top2 phosphorylation sites identified by Phos-
tag analysis, we also performed mass spectrometric analysis of
the protein. Mitotic cells expressing FLAG-tagged Top2 pro-
teins under the native promoter were collected, and Top2
proteins were immunoprecipitated by anti-FLAG antibody
(Fig. S2A). LC-MS analysis of precipitated Top2 protein iden-
tified six putative phosphorylation sites at Ser1310, Ser1363,
Ser1416, Thr1417, Ser1431, and Ser1433, all of which were located
in the C-terminal region (Fig. S2, B and C). Thus, phosphoryla-
tion at Ser1363 was confirmed by mass spectrometric analysis
but that at Ser1364 was not. Previous comprehensive phosphor-
ylation analyses in S. pombe cells reported both Ser1363 and
Ser1364 as phosphorylation sites (39–42). The reason why our
analysis failed to detect Ser1364 phosphorylation is unclear. Fur-
ther consideration of experimental conditionsmay be required.
Preparation of polyclonal antibodies against two
phosphopeptides containing phosphorylated Ser1363
or Ser1364
To detect phosphorylation of the two CKII sites, antibodies
were raised against twophosphopeptides containing phosphor-
ylated Ser1363 or Ser1364 residues (phospho-Ser1363 or phospho-
Ser1364) (see “Experimental procedures”). The resulting anti-
bodies were then used for immunoblotting of FLAG-tagged
Top2 in WT and alanine mutant cell extracts (S1363A or
S1364A). Phosphorylated Ser1363 and Ser1364 bands were de-
tected in WT cell extracts but were almost undetectable in the
alanine mutants, demonstrating that the phosphopeptide anti-
bodies were specific for phospho-Ser1363 or phospho-Ser1364
(Fig. 2, A and B).
We tested in vitro phosphorylation of Top2 by CKII. Immu-
noprecipitated S. pombe Top2 proteins were treated with 
protein phosphatase, and the resulting dephosphorylated Top2
proteins were incubated with human CKII protein complex
( and  subunits) (“Experimental procedures”). Anti-Top2
phospho-Ser1363 and phospho-Ser1364 antibodies detected the
rephosphorylated Top2 protein bands in an immunoblot assay,
suggesting that CKII directly phosphorylates Ser1363 and
Ser1364 residues (Fig. 2C).
Phosphorylation of Ser1363 and Ser1364 is diminished in CKII
temperature-sensitivemutants
To determine whether phosphorylation of Top2 Ser1363 and
Ser1364 depended on CKII, phospho-antibodies were used to
immunoblot cell extracts obtained from two distinct tsmutants
of the CKII catalytic subunit Cka1, cka1–372 (newly identified
in this work) and cka1/orb5-19 (43) (Fig. S3A). The mutation
site of cka1–372 is identified asH152Y,which is located close to
Effect of topo II phosphorylation on ICRF-193 treatment
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Figure 2. Top2 Ser1363 and Ser1364 are phosphorylated by CKII throughout the cell cycle. A and B, the specificity of polyclonal antibodies against
phospho-Ser1363–containing (A) and phospho-Ser1364–containing (B) phosphopeptides was examined. Asynchronous extracts of the strain expressing FLAG-
taggedWTTop2proteinornonphosphorylatable alaninemutantsof Top2 (S1363Aor S1364A)proteinswerepreparedand runonSDS-PAGE. Ponceau staining
was used for the loading control of extracts. C, Ser1363 and Ser1364 were phosphorylated by CKII in vitro. Immunoprecipitated Top2-FLAG proteins were
dephosphorylated by  protein phosphatase and then incubated with CKII. Anti-Top2 phospho-Ser1363 and -phospho-Ser1364 antibodies were used to detect
rephosphorylation by CKII.D, phosphorylation of Ser1363 and Ser1364was diminished in twodistinct alleles of CKII tsmutants, cka1-372 and orb5/cka1-19, at the
restrictive temperature (36 °C for 6 h). Cell extractswere prepared inWT, cka1-372, orb5/cka1-19 and tor2-Smutants expressing Top2-FLAGprotein at 26 °C and
36 °C (6h) alongwith theuntagged strain. The tor2-Smutantwasusedas a control strain (55),which shows small cells as observed in cka1-372 and cka1/orb5-19
mutant cells at the restrictive temperature (Fig. S3A). Top2 proteinswere detectedwith anti-FLAG antibodies in the presence (Phos-tag) or absence (normal) of
25 M Phos-tag. Top2 Ser1363 and Ser1364 phosphorylation was detected using anti-phospho-Ser1363 and anti-phospho-Ser1364 antibodies, respectively.
Anti-PSTAIR (Cdc2) antibody was used for a loading control of extracts. The asterisk indicates nonspecific bands that probably appear under delay or arrest of
cell-cycleprogression, suchasundernitrogen starvation (F), UV irradiation (Fig. S5), and low-glucose conditions (Figs. S4A andS5). Because FLAG taggingpartly
reduces the Top2 protein level (Fig. S4B), both phospho-specific antibodies give a weaker signal in FLAG-tagged strains relative to untagged strains. E, Ser1363
and Ser1364 were phosphorylated throughout the cell cycle. Block and release of cdc25-22 mutant cells expressing Top2–3FLAG was done for synchronous
culture commencing from late G2 phase to mitosis. Immunoblotting was performed with antibodies against FLAG, Top2 phospho-Ser
1363 and phospho-
Ser1364. Cut2 (securin) and Cdc13 (mitotic cyclin) are shown as mitotic progressionmarkers. Cell cycle progression was monitored by counting the number of
binucleate cells lacking (blue, anaphase–telophase) and possessing septa (red, G1/S phase). F, top panel, Top2 phosphorylation was examined in nitrogen-
starved,WT, G0-arrested cells, whichwere then permitted to proliferate by addition of a nitrogen source (44). Immunoblottingwas performedwith antibodies
against FLAG, Top2 phospho-Ser1363, and tubulin (a loading control) as shown in D. Bottom panel, FACScan analysis indicating the timing of S phase (5–6 h).
Top2 phosphorylation did not change during nitrogen starvation or after release.
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the kinase active site (Fig. S3B). At 26 °C, phosphorylated
Ser1363 and Ser1364 bands were detected by specific phospho-
antibodies in all tested cell extracts (Fig. 2D). In Phos-tag anal-
ysis, there are no significant differences in electrophoretic
mobility of Top2–3FLAG proteins among these extracts. At
36 °C, however, phospho-Ser1363 and phospho-Ser1364 were
diminished in both cka1–372 and cka1/orb5-19 mutant cells.
Consistently, Top2 proteins showed fastermobility in Phos-tag
gels in these mutants, strongly suggesting that CKII is respon-
sible for phosphorylation of Top2 at residues Ser1363 and
Ser1364.
Top2 Ser1363 and Ser1364 are constitutively phosphorylated
throughout the cell cycle
We then performed a block–release experiment using the
cdc25-22 ts mutant to examine whether phosphorylation of
Ser1363 and Ser1364 changes in any cell cycle stage. cdc25-22
cells expressing Top2–3FLAG were blocked in late G2 and
released synchronously into mitosis by a shift in temperature
from 36 °C to 26 °C. Bands of phospho-Ser1363 and phospho-
Ser1364 were almost constant throughout the cell cycle,
although phospho-Ser1363 and overall phosphorylation of
Top2–3FLAG (Phos-tag gel) were slightly more intense at 30
and 45 min, which correspond to early mitosis (Fig. 2E).
We also examined Top2 phosphorylation in nitrogen-
starved, WT, G0-arrested cells, which were then permitted to
proliferate by addition of a nitrogen source (44). The level of
phosphorylation at Top2 Ser1363 in G0 was comparable with
that in asynchronous culture and not significantly changed in
proliferative cells (Fig. 2F). Therefore, these results indicate
that CKII-dependent phosphorylation at Ser1363 and Ser1364 is
maintained throughout the cell cycle.
Unphosphorylatable Top2-2Amutant proteinmaintains DNA
decatenation activity but partly decreases ATPase activity
S. pombe Top2 protein dephosphorylated by potato acid
phosphatase is still enzymatically active (25). To address the
question of whether the enzymatic activity of Top2 is affected
by phosphorylation of Ser1363 and Ser1364, we analyzed DNA
decatenation activity using Top2 WT and unphosphorylatable
2A (S1363A S1364A) mutant proteins. FLAG-tagged Top2-
WT and -2A proteins were overproduced under the inducible
nmt promoter inWT cells and immunoprecipitated using anti-
FLAG antibody (Fig. 3A). Immunoprecipitated Top2 proteins
were incubated with kinetoplast DNA (kDNA) in the presence
of ATP for 1–30 min at 37 °C (see “Experimental procedures”).
The results indicate that both Top2-WT and -2A proteins
decatenated kinetoplast DNA within 10 min (Fig. 3B). Thus,
consistent with previous work, CKII-dependent phosphoryla-
tion at Ser1363 and Ser1364 presumably did not affect the decat-
enation activity of Top2.
Next we assayed the ATPase activity of Top2 WT and 2A
mutant proteins. Immunoprecipitated Top2 proteins were
incubated with ATP in the presence of kDNA for 30 min, and
resulting free phosphate was measured by malachite green col-
orimetric assay (see “Experimental procedures”). The ATPase
activity of unphosphorylatable Top2 2Amutant proteins partly
decreased to 60% compared with WT proteins (Fig. 3C). In
the presence of an anticancer drug, ICRF-193, which inhibits
the ATPase activity of topo II protein (15, 16), bothWT and 2A
mutant proteins lost much of their ability to hydrolyze ATP.
This result suggests that CKII-mediated Top2 phosphorylation
at Ser1363 and Ser1364 facilitates ATP hydrolysis.
More severe defects in chromosome segregation occur in
cka1–372mutant cells treatedwith a topo II inhibitor,
ICRF-193
To investigate the functional relationship between CKII and
Top2 in mitosis, we analyzed chromosome segregation in
cka1–372 mutant cells in the presence of ICRF-193. WT and
cka1–372mutant cells were cultivated at 26 °C and then shifted
to 36 °C for 3 h in the presence or absence of 5 or 10 M ICRF-
193. In the absence of the drug (mock treatment with DMSO),
neitherWTnor cka1mutant cells produced abnormal segrega-
tion of mitotic chromosomes (Fig. 4A). On the other hand, the
cka1 mutant failed to segregate chromosomes to a greater
extent than WT cells in the presence of 5 or 10 M ICRF-193.
The drug-treated cka1mutant showed a “displaced nucleus” in
one daughter cell, which is a more severe segregation defect
than partial mis-segregation, such as lagging or streaked chro-
mosomes, as observed in drug-treated WT cells. These obser-
vations indicated that inhibition of Top2 activity and loss of
CKII function additively interfere with mitotic chromosome
segregation.
ICRF-193–induced chromosomemis-segregation is
exacerbated in top2-2Amutant cells
Todetermine the contribution of phospho-Ser1363 and phos-
pho-Ser1364 to chromosome segregation, we observed the
mitotic phenotype of Top2 WT, 2A unphosphorylatable, and
phosphomimetic 2E mutant cells in the presence or absence of
ICRF-193. DMSO treatment did not cause segregation defects
in any tested strains (Fig. 4B). In ICRF-193–treated WT cells,
9% of anaphase cells showed abnormally streaked chromo-
somes; however, the frequency of defective segregationwas sig-
nificantly increased in top2-2A mutant cells, in which 25% of
anaphase cells produced abnormally streaked chromosomes.
Segregation defects in top2-2Emutant cells were observed to a
lesser extent than in 2A mutant cells. Thus, phosphorylation
at Ser1363 and Ser1364 apparently increases the fidelity of
chromosome segregation when Top2 function is impaired by
ICRF-193.
Discussion
So far as we are aware, our results provide the first evidence
that CKII-mediated phosphorylation of the topo II CTD sup-
presses sensitivity to topo II catalytic inhibitors. Topo II phos-
phorylation confers resistance to DNA double-strand break–
inducing topo II poisons onmammalian cells (45, 46). Actually,
the phosphorylation level of topo II protein is increased in topo
II poison–resistant human cancer cells (47). Thus, when either
type of anti-topo II drug is applied, inhibition of topo II phos-
phorylation may additively interfere with mitotic chromosome
segregation.
How does topo II phosphorylation diminish the inhibitory
effect of ICRF-193 on chromosome segregation? ICRF-193
Effect of topo II phosphorylation on ICRF-193 treatment
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traps the topo II–DNA complex in a closed, clamped config-
uration by inhibiting its ATPase activity (15, 16). Contrarily,
ATP hydrolysis is stimulated 2.7-fold after topo II phosphor-
ylation by CKII inDrosophila cells (29). Therefore, ICRF-193
and CKII-mediated topo II phosphorylation have an antag-
onistic effect on the ATPase activity of topo II. Topo II
hydrolyzes ATP at the end of the catalytic cycle after dsDNA
passage and religation reactions and is a prerequisite for
topo II turnover on DNA (29). It is thus suggested that ICRF-
193 interferes with the release of topo II protein from chro-
mosome DNA; however, CKII promotes topo II transloca-
tion along the DNA through phosphorylation. In this
study, we show that Top2 unphosphorylatable 2A (S1363A,
S1364A) mutations partly decrease ATPase activity (Fig.
3C). The phosphorylated topo II residues Ser1363 and Ser1364
may directly modulate the ATP-binding catalytic domain,
which is targeted by ICRF-193, or indirectly associate with
the domain through DNA binding (Fig. 5). In the presence of
ICRF-193, we could not detect a statistically significant dif-
ference in ATPase activity between Top2-WT and -2A pro-
Figure 3. Top2–2A (S1363A,S1364A) mutant protein maintains decatenation activity but has reduced ATPase activity. A, SDS-PAGE patterns of WT
Top2 and alanine substitution mutant Top2-2A (S1363A and S1364A). FLAG-tagged Top2-WT and -2A proteins were overproduced under the inducible nmt
promoter (plasmid Rep41) in WT S. pombe cells and immunoprecipitated using anti-FLAG antibody. A strain containing only the vector was used as a control.
Immunoprecipitated FLAG-tagged Top2 proteins are indicated by arrows. The position of the protein marker bands (M) is indicated. B, Top2 decatenation
assay. kDNA(153ng)was incubatedwith immunoprecipitatedTop2fractions inATP-containingreactionbuffer (see“Experimentalprocedures”) for1–30minat37 °C.
An immunoprecipitated fraction fromcell extracts containingonly the empty vectorwasused for amock reaction (vector IP). The reactionwas terminatedusing stop
buffer and loadedontoa1%agarosegel followedbyethidiumbromide staining.Only thecatenatedkDNA (kDNA) anddecatenatedkDNA (decat. kDNA)were loaded
as controls, alongwithDNAdigestedbyEcoT14I (-EcoT14I). Positionsof catenatedanddecatenatedkDNAare indicatedbyanarrowanda vertical line, respectively.
The ratio of decatenated DNA to total DNA (catenated decatenated) was quantified. Phosphorylation of Ser1363 and Ser1364 does not affect Top2 decatenation
activity. C, Top2 ATPase assay. Immunoprecipitated Top2-WT or -2A mutant proteins were incubated with ATP and kDNA in the presence or absence of the 5 M
anti-cancer topo II inhibitor ICRF-193 for 30 min at 30 °C. Free phosphate produced by ATP hydrolysis was measured by malachite green colorimetric reagent (see
“Experimental procedures”). Error bars represent the standard deviation for each experiment performed in triplicate. p values for comparison among four conditions
were calculated using one-way analysis of variancewith Holmmulti-comparison correction. *, p 0.05.
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teins, implying that additional phosphorylation sites may be
involved in modulation of the activity. Further study is
required tounderstand themolecular actionof the phosphor-
ylated topo II CTD on its catalytic ATPase domain.
It has been reported that topo II CTD is mitotically SUMO-
ylated and that this modification is required for Topo II accu-
mulation at centromeres in Xenopus egg extracts (32, 48–50).
Phosphorylated topo II protein was also enriched at centro-
meric DNA in human cells (51, 52). This evidence supports the
idea that posttranslational modification of topo II CTDmodu-
lates association and dissociation of topo II protein with chro-
mosome DNA.
We demonstrated that CKII-dependent phosphorylation at
the Top2 residues Ser1363 and Ser1364 ismaintained throughout
the entire cell cycle. This result is consistent with the constitu-
tive activation of CKII in various organisms (53, 54). CKII is a
ubiquitous, essential kinase for a wide variety of cellular func-
tions, including transcription, heat shock response, target of
rapamycin complex–mediated nutrient signaling, and mainte-
nance of cell morphology, indicating its pivotal role in cell pro-
liferation (38, 43, 55–59). Therefore, it is assumed that CKII
persistently relieves the topological constraints upon DNA
through the phosphorylation of Top2 Ser1363 and Ser1364 at any
cell cycle stage. To deal with simultaneous and multiple occur-
rences of topological stress along chromosomal DNA, consti-
tutive phosphorylation of the Top2 CTD by CKII is probably
essential for the continuous action of Top2 molecules.
The phosphorylation status of Top2 Ser1363 and Ser1364 did
not change under any tested stressful conditions, including UV
exposure, heat shock, osmotic stress, low glucose, and nitrogen
starvation (Fig. S5). In addition, top2-2Amutant strains did not
show any sensitivities to DNA damage–inducing agents or
nutritional limitation as far as we could determine, suggesting
that phosphorylation at Top2 Ser1363 and Ser1364 is not in-
volved in these stress responses. An alternative possibility is
that the constitutively phosphorylatedTop2CTD is targeted by
specific factor(s) and loaded onto chromosomal DNA under
stressful physiological conditions.
CKII protein levels are consistently higher in tumors than in
normal tissues, and overexpression of CKII has been reported
Figure 4. Defective chromosome segregation induced by an anti-cancer catalytic topo II inhibitor, ICRF-193, is exacerbated in cka1-372 and top2-2A
(S1363A,S1364A)mutant cells.A, CKII tsmutant cka1-372 cells showedmore severedefects inmitotic chromosomesegregation thanWTcells in thepresence
of ICRF-193. Left panel, DAPI-stainedmicrographs of WT and cka1-372mutant cells were obtained at the restrictive temperature (36 °C) for 3 h in the presence
of DMSO or ICRF-193 (5 and 10 M). A displaced nuclear phenotype was frequently observed in ICRF-193–treated cka1 mutant cells (arrows). Right panel,
frequencies of defective phenotypes categorized as lagging-like (blue), streaked chromosomes (red), and displaced nucleus (green). More than 200 anaphase cells
were counted for each sample.Error bars represent the standarddeviation for eachdefectivephenotypes.pvalues for comparisonbetween thedrug-treatedWTand
cka1mutant were calculated using a Student’s t test. *, p 0.05; **, p 0.01 (black, total frequency of abnormal phenotypes; color, each phenotype). B, defects in
chromosome segregation increased significantly in unphosphorylatable top2-2A mutants compared with WT and phosphomimetic top2–2E mutant cells in the
presenceof ICRF-193. Cellswere asynchronously cultured at 26 °C for 2h in thepresenceofDMSOor 5M ICRF-193. Left panel, representativemicrographsofDMSO-
and 5M ICRF-193–treated top2-2A cells. ChromatinDNAwas stainedwithDAPI. Abnormally streaked chromosomes in anaphase are indicated (arrows). Scale bar
10m. Right panel, frequencies of anaphase cells with abnormally streaked chromosomes. More than 200 anaphase cells were counted for each sample. Error bars
represent the standard deviation for each experiment performed in biological triplicates. Significant differences among the three strains were examined using
one-way analysis of variancewith Bonferronimulti-comparison correction. *, p 0.05; **, p 0.01; n.s., not significant.
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to cause neoplastic growth in animal cells (60). These facts have
increased interest in CKII as a target of anticancer chemother-
apy (61–63). Indeed, potent inhibitors against CKII have been
developed and applied (64, 65). We assume that higher
amounts of anti-topo II drugsmay be required to inhibitmitotic
progression in which hyperactivated CKII accelerates cell pro-
liferation. Thus, our results suggest possible benefits of
applying CKII inhibitors in combination with topo II cata-
lytic inhibitors for effective prevention of mitotic chromo-
some segregation in tumor cells.
Experimental procedures
Strains, plasmids, andmedia
The S. pombe haploid WT strain 972 h and its derivative
mutant strains, including the ts orb5-19 (43), tor2-S (L2048S)
(55), cdc25-22 (66) and the cs nda3-KM311 (67), were used.
The ts cka1–372mutant was newly isolated from a collection of
1015 ts strains (68). A strain with chromosomally integrated
3FLAG-tagged Top2 has been described previously (35). For
Top2 alanine or glutamate mutants, site-directed PCR-based
mutagenesis was used. Briefly, complementary pairs of oligo-
nucleotide DNAs with mutations were used as PCR primers,
followed by two rounds of PCR. The mutated top2 gene was
cloned and chromosomally integrated with the FLAG tag, the
adh1 3 UTR, and the kanamycin-resistant gene kanR into
the endogenous top2 locus of the WT strain 972 h. Correct
integration was confirmed by PCR and digestion of the PCR
products with restriction enzymes. To construct the 3FLAG-
tagged Top2 C-terminal deletion mutants, top2 gene frag-
ments were amplified by PCR and chromosomally integrated
under the native promoter in the samemanner. pRep81 plasmids
expressing FLAG-tagged N- and/or C-terminal deletion mutant
proteins were constructed by PCR amplification. ICRF-193
(Zenyaku Kogyo, Tokyo, Japan) was dissolved in DMSO and
added to culturemedia to a final concentration of 5 or 10M (20).
Synchronous culture
For the block-and-release experiment using the cdc25-22
mutant (66), cells were grown in YPD at 26 °C (to 3 	 106
cells/ml) and then shifted to 36 °C for 4.25 h to block cells in late
G2 phase. Cells were then released to 26 °C, and aliquots were
taken every 15 min for immunoblotting and determination of
the septation index. Mitotically arrested cells using the nda3-
KM311 cold-sensitive mutant were prepared as described pre-
viously (67). For nitrogen starvation and release, cells were
transferred to nitrogen-deficient Edinburgh Minimal Medium
2 (EMM2-N)medium at 26 °C for 24 h and then replenished by
addition of 0.5% NH4Cl (44). FACScan analysis was carried out
as described previously (20).
Immunochemistry and phosphate-affinity SDS-PAGE
Protein extracts were prepared by cell breakage using glass
beads in extraction buffer (25 mM Tris-HCl (pH 7.5), 0.1%
NP-40, 10% glycerol, and 1 mM DTT) supplemented with pro-
tease inhibitor mixture (Sigma). Extracts were boiled with lith-
ium dodecyl sulfate (LDS) sample buffer (Invitrogen) and
loaded onto 6% or 12% polyacrylamide gels. Phosphate-affinity
SDS-PAGE was carried out using Phos-tag acrylamide
(NARD Institute) following the manufacturer’s instructions. 
PPase (New England Biolabs) was used for phosphatase treat-
ment. PPase-treated or untreated cell extracts were run on
polyacrylamide gels containing Phos-tag acrylamide and
MnCl2. To increase transfer efficiency, manganese ions were
eliminated from the gel by soaking it in transfer buffer contain-
ing 1 mM EDTA. Immunoblotting was performed using the fol-
lowing antibodies: anti-FLAG M2 (Sigma), anti-PSTAIR (a gift
fromDr. Y. Nagahama, National Institute for Basic Biology, Oka-
zaki, Japan), anti-Cut2 (69), and anti-Cdc13 (70). Top2 phospho-
antibodies were obtained by immunizing rabbits with synthetic
phosphopeptides (Sigma): (1351-RKTNKPVATTIF[S-phos]S-
DDEDD-1369) for anti-Top2 phospho-Ser1363 and (1351-RK-
TNKPVATTIFS[S-phos]
DDEDD-1369) for anti-Top2 phospho-Ser1364. Intensity of
protein bands was measured using the image analysis software
ImageJ (National Institutes of Health). Mass spectrometric
analysis for identification of Top2 phosphorylation sites was
performed as described previously (10).
In vitro phosphorylation of Top2 protein
To prepare Top2-WT protein, pRep41 plasmid expressing
the protein under the inducible nmt promoter was transformed
in the S. pombeWT strain. The resulting strain was cultured at
26 °C for 24 h in the absence of thiamine to induce FLAG-
tagged Top2 proteins, and then 1 	 109 cells were collected.
Frozen cells were disrupted and immunoprecipitated using
anti-FLAG M2–agarose beads (Sigma) as described previously
(10). For the in vitro phosphorylation assay, immunoprecipi-
tated Top2 proteins (20 ng) were treated with 400 units of 
Figure 5. Cartoon of the possible action of phosphorylated topo II resi-
dues Ser1363 and Ser1364 on the ATP-binding and hydrolysis domain tar-
geted by ICRF-193. AnATP-binding hydrolytic domain (green), a DNA-binding
cleavage domain (light blue), and a C-terminal region (blue) are illustrated with
gate (G) and transport (T) segments of dsDNAs. The T-shaped line represents the
inhibitionoftheATP-bindinghydrolyticdomainbyICRF-193(astructural formula
is shown). Thedashedarrow represents thepossible actionof the topo II residues
Ser1363 and Ser1364 phosphorylated by CKII. See text formore details.
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protein phosphatase (New England Biolabs, P0753) for 30 min
at 30 °C. Dephosphorylated Top2 proteins were incubated with
500 units of casein kinase II protein complex ( and subunits)
derived from human cells (New England Biolabs, P6010) in the
presence of 200MATP for 30min at 30 °C. Rephosphorylated
Top2 proteins were immunoblotted by anti-Top2 phospho-
Ser1363 and phospho-Ser1364 antibodies.
Fluorescencemicroscopy
DAPI staining was carried out as described previously (71).
All-in-onemicroscopes (BZ9000 and BZ-X700, Keyence), were
used to observe glutaraldehyde-fixed cells.
Top2 decatenation assay
pRep41 plasmids expressing FLAG-tagged Top2-WT or -2A
proteins under the inducible nmt promoter were constructed
and transformed in the S. pombe WT strain. The resulting
strains were cultured at 26 °C for 24 h in the absence of thia-
mine, and then Top2-FLAG proteins were immunoprecipi-
tated using anti-FLAGM2–agarose beads (Sigma) as described
previously (10). Top2 decatenation assays were performed
using the Topoisomerase II Assay Kit (TopoGEN, Inc.,
TG1001-1). Kinetoplast DNA (153 ng) was incubated with the
Top2 IP fraction (5 ng) at 37 °C for 1–30 min in reaction
buffer (50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 10 mMMgCl2,
0.5 mMDTT, 30 g/ml BSA, and 2mMATP). The reaction was
terminated with stop buffer (1% sarkosyl, 0.025% bromophenol
blue, and 5% glycerol). Samples were run on a 1% agarose gel in
1	 Tris borate-EDTA at 135 V for 25 min and stained with
ethidiumbromide. Intensity ofDNAbandswasmeasured using
ImageJ (National Institutes of Health).
Top2 ATPase assay
S. pombe Top2 proteins were immunoprecipitated as de-
scribed above and subjected to amalachite green assay using an
ATPase/GTPase activity assay kit (Sigma, MAK113). Kineto-
plast DNA (270 ng) was incubated with the Top2 IP fraction
(0.1 g) in assay buffer containing 40 mM Tris, 80 mM NaCl,
8mMMgAc2, and 1mMEDTA (pH7.5). Assayswere performed
in the presence or absence of 5M ICRF-193 at 30 °C for 30min
in triplicate. The resulting colorimetric product was measured
at 600 nm with a spectrophotometric plate reader (ARVO X3,
PerkinElmer Inc.). The immunoprecipitated fraction from a
strain expressing an empty vector was also assayed and used as
a background control. Background readings could then be sub-
tracted from sample readings.
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